Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA )

2.844 -0.086 (-2.94%)
Streaming Delayed Price Updated: 3:54 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,006
Open 2.920
Bid (Size) 2.800 (1)
Ask (Size) 3.500 (7)
Prev. Close 2.930
Today's Range 2.821 - 2.930
52wk Range 2.050 - 3.830
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+2.29%
+2.29%
1 Month
-4.57%
-4.57%
3 Month
-3.60%
-3.60%
6 Month
-8.41%
-8.41%
1 Year
+31.05%
+31.05%

More News

Read More
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
Via Investor Brand Network
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For Lisata Therapeutics
Via Benzinga
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Via Benzinga
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via News Direct
Exposures Product Safety
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via TheNewswire.com
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.